CYT News and Press, Cyteir Therapeutics Inc. From 01/03/22

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will present at the 40th Annu...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics...

Cyteir Therapeutics (NASDAQ:CYT): Q3 GAAP EPS of -$0.33 beats by $0.02. Cash and cash equivalent of $199.82M. Press Release For further details see: Cyteir Therapeutics EPS beats by $0.02

- Phase 2 dose identified for CYT-0851 and initiation activities ongoing for Phase 2 monotherapy expansion study and Phase 1/2 combination studies - Ended quarter with approximately $200 million in cash to continue to advance our pipeline and to fund operations through 2023 ...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presenta...

A record 62 recent IPOs joined the Russell 2000 small-cap index this month. Here's a look at some of the biotech stocks that just joined: Lyell Immunopharma Lyell Immunopharma (NASDAQ:LYEL), which is developing T cell therapies for solid tumors, had a 25M-share IPO in June expected to net pro...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market opens on ...

Lightstone Ventures Raises $375 Million Fund Fund III will continue firm's work partnering with entrepreneurs developing breakthrough therapies and medical technologies Christina Isacson, Ph.D., joins as Partner and Young Kwon, Ph.D., as Operating Partner PR Newswire ...

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside...

Point Roberts, WA and Delta, BC - August 27, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, cannabis, mining, cleantech and psychedelics. Today's stocks have been added...